In healthy individuals, studies indicate that the effects of these two hormones are additive (48, 54)
The idea behind microdosing is to achieve some of the benefits of the drug, such as weight loss or blood sugar control, while minimizing side effects like gastrointestinal discomfort, which is commonly reported with full doses
Thus, the effectiveness of the product is reduced, and patients cannot get the desired effect, which may potentially be dangerous (for example, people may experience sudden blood sugar spikes)
& Fimia, G
25 , 11471159.e10 (2017)
In a rodent model, a novel GLP-1R/GIPR/GCGR triple agonist, SAR441255, has been shown to promote weight loss and the maintenance of healthy blood glucose levels and is superior to the GLP-1R/GCGR dual agonist (Bossart et al., 2022)